Germany Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027

Germany's antirheumatic drug market was valued at US$7,533.165 million in 2020. The market is projected to grow at a CAGR of 4.08% to attain a value of US$9,964.630 million by 2027. The antirheumatic drug market in Germany is projected to show nominal growth over the course of the next five years due to the growing geriatric population along with the presence of a well-established healthcare sector in the country. The booming healthcare expenditure in the country is also bolstering the anti-rheumatic drug market growth in the country throughout the forecast period. As per the data from the Federal Statistical Office (Destatis), in 2018, healthcare expenditure in Germany reached 387.7 billion euros, an increase of 3.1% from the previous year. Furthermore, the country is also a well-known location for pharma companies in the field of research for medicines related to various chronic diseases, which is also anticipated to add impetus to the market growth in the upcoming years.

Moreover, the growing geriatric population also plays a crucial role in driving the market growth in Germany, owing to the fact that old people are more susceptible to various rheumatic diseases. According to the data from the World Bank Group, the percentage of the geriatric population in the country reached 21.642% by 2018 from 20.024% in 2008. Furthermore, the high consumption of generic drugs in the country owing to the cheaper costs associated with these types of drugs will further act as a contributing factor for the market to grow in the coming years. For instance, according to reports from the German Trade and Invest, the share of generic medicines in Germany reached 77% in volume terms during the year 2015 and was projected to grow in the coming years, thereby providing an impetus for the market to grow in the coming years.

The German antirheumatic drug market has been segmented on the basis of the type of disease, type of molecule, and sales channel. On the basis of the type of disease, the market has been classified into osteoarthritis, rheumatoid arthritis, gout, lupus, and others. The market has been segmented based on molecule type; the market has been segmented based on pharmaceuticals and biopharmaceuticals. By the sales channel, the segmentation has been done on the basis of prescription and over-the-counter (OTC).

Key Developments in the Market:

• In August 2020, Mylan N.V. and Lupin Limited (Lupin) launched Nepexto®, a biosimilar to etanercept, in the German market. Nepexto® has been approved to treat moderate to severely active rheumatoid arthritis, juvenile idiopathic arthritis starting at age 2, and active and progressing psoriatic arthritis at age 6, among several other conditions.
• In June 2021, as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals, Royalty Pharma plc, and German-based MorphoSys AG announced a strategic financing agreement worth $2.025 billion. The acquisition by Royalty Pharma of MorphoSys' rights to obtain future royalties on Tremfya is the cornerstone of this finance partnership. Tremfya is an anti-interleukin (IL)-23 that has been licensed for the treatment of people with moderate to severe plaque psoriasis and for individuals with active psoriatic arthritis.

COVID-19 Insights:

COVID-19 had a significant impact on the German antirheumatic drugs market. The growing prevalence of rheumatic patients led to the increased demand for drugs in the country. Nevertheless, the enforcement of the lockdown and social distancing measures by the German government led to the closure of many production facilities and low staffing, reducing productivity. The travel restrictions also affected the exports and imports of the market, creating a gap in the supply and demand chain. The aforementioned factors slowed down the market's growth.

Segmented

By Type of Disease

• Osteoarthritis
• Rheumatoid Arthritis
• Gout
• Lupus

By Drug Class

• Disease-modifying Anti-Rheumatic Drugs (DMARDs)
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• JAK inhibitor

By Sales Channel

• Prescription
• Over-The-Counter (OTC)